TYSABRI

Indicated For

Multiple Sclerosis, Crohn's Disease

About This Medication

# Biogen Support Services Patient Guide: How to Get TYSABRI at Low or No Cost ## About TYSABRI TYSABRI (natalizumab) is a prescription medication used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1] As a disease-modifying therapy, TYSABRI can help reduce the frequency of relapses and slow disease progression. However, the cost of this medication can be significant, which is why Biogen offers financial assistance programs to help eligible patients access their treatment. ## Who Qualifies for Assistance Biogen Support Services offers different assistance options depending on your insurance status:[1][4] **Commercially Insured Patients**: If you have private insurance, you may qualify for the Biogen Copay Program, which can reduce your out-of-pocket costs to as little as $0 per dose. **Government Insured Patients**: If you have Medicare, Medicaid, VA/DoD coverage, or other federal plans, Biogen Support Coordinators can help you explore alternative government insurance programs and other assistance options. **Uninsured or Underinsured Patients**: Biogen can research other possible financial assistance available to you through various programs and resources. ## Income Eligibility Unlike many traditional patient assistance programs, Biogen's support services do not use strict income thresholds to determine eligibility.[1][4] Instead, eligibility is primarily based on your insurance status and financial responsibility for your medication. This means that even patients with moderate incomes may qualify for assistance if they have significant out-of-pocket costs. However, certain restrictions apply: patients covered by Medicare, Medicaid, the VA/DoD, TRICARE, or other federal healthcare programs are not eligible for the Biogen Copay Program, though they may qualify for other assistance options.[1] ## Insurance Requirements and Restrictions | Insurance Type | Copay Program Eligible | Other Assistance Available | |---|---|---| | Commercial Insurance | Yes | Yes | | Medicare | No | Yes | | Medicaid | No | Yes | | VA/DoD | No | Yes | | TRICARE | No | Yes | | Uninsured/Underinsured | No | Yes | Additional restrictions for the Copay Program include:[1] - You cannot be a resident of Massachusetts or Rhode Island - You must have a financial responsibility or copay for your infusion - You must not be covered by state medical or pharmaceutical assistance programs - You must have a US prescriber and US shipping address or administration site ## The Biogen Copay Program: Coverage Details If you qualify for the Biogen Copay Program, here's what you need to know:[3] **Drug Copay Assistance**: Covers the cost of the TYSABRI medication itself, with an annual cap of assistance. **Administration Copay Assistance**: Covers costs associated with administering TYSABRI, up to $250 per infusion or $3,250 per year, whichever is reached first. **Important Limitation**: Once you reach the maximum annual assistance ($3,250), you will be responsible for 100% of your copay and procedure costs for the remainder of that calendar year. **What's Not Covered**: The copay program does not cover copays related to office visits, network penalties, or other costs beyond the drug and administration. ## Step-by-Step Application Process **Step 1: Contact Biogen Support Services** Call 1-800-456-2255 Monday through Friday from 8:30 AM to 8 PM ET.[2] A Biogen Support Coordinator will answer your call and begin the enrollment process. **Step 2: Provide Insurance Information** Your Support Coordinator will ask about your current insurance coverage, including your insurance company name, policy number, and any copay or coinsurance amounts you're responsible for. **Step 3: Verify Eligibility** The coordinator will verify that you meet all eligibility requirements for the assistance program that best fits your situation. **Step 4: Insurance Communication** Biogen Support Coordinators will communicate directly with your insurance company to explain coverage options and costs, including guiding you through the Prior Authorization process if needed.[1] **Step 5: Enrollment Confirmation** Once approved, you'll receive confirmation of your enrollment and details about how your assistance will be applied to your prescriptions. ## Timeline and Delivery While specific processing times are not publicly detailed, Biogen Support Services is designed to help you get started on TYSABRI as quickly as possible.[2] Once you're prescribed TYSABRI, you can contact Biogen immediately to begin the assistance process. Your Support Coordinator will work with your healthcare team and insurance company to expedite approval. TYSABRI is administered as an intravenous infusion, typically at an authorized infusion center. Biogen can help you locate an authorized infusion center near you and coordinate your treatment schedule. ## What Happens If Your Application Is Denied If you don't qualify for the Biogen Copay Program, you still have options:[1][4] - Biogen Support Coordinators can help identify alternative financial assistance programs - For government-insured patients, they can research eligibility for alternative government insurance programs - For uninsured or underinsured patients, they can research other possible financial assistance available to you - You can contact the National MS Society or MSAA (Multiple Sclerosis Association) for additional resources and support programs ## Important Disclaimers This guide provides general information about Biogen's patient assistance programs. Eligibility requirements, program terms, and assistance amounts are subject to change. Federal and state laws may prevent or restrict eligibility for certain patients. Always verify current program details by calling Biogen Support Services at 1-800-456-2255 or visiting the official TYSABRI website. Your healthcare provider is your best source for medical information about TYSABRI and whether it's appropriate for your condition.

Program information last verified: March 30, 2026